08/21/2000 RHARM Sale_Ref: 000000

01 FC:148

110.00 CH

6506386677

T-024

P.007/007

PTO/SB/26 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are regulred to respond to a collection of information unless it displays a valid QMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT			4264C4
	In re Application of		
Į.	Livak et al.		
	Application remoci		November 8, 1999
	09/436,454		Adventiber 6, 1999
For Hybridization Assay Using Self-Quenching Fluorescence Probe			
	Group Art Unit	Examiner	
	1656	J. Riley	
The Perkin-Elmer Corporation, the nereby disclaims, except as provided bustant application, which would extend to 156 and 173 as shortened by any tethat any patent so granted on the instantiant prior patent are commonly owned, is binding upon the grantee, its successing	pelow, the terminal persons the expiration of th	part of the statutory terms on date of the full statutory for Patent No. 5,538,84 e enforceable only for and s with any patent granted	term defined in 35 U.S.C. 154 48. The owner hereby agrees during such period that it and on the instant application and
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.			
Check either box 1 or 2 below, if appropriate.			
1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.			
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.			
2. The undersigned is an attorne	ey of record.		
July 26, 2000 Date		Mass A Sign	ature
,		Vincent M. Powers Typed or printed name	36,246 Reg. No.
Terminal disclaimer fee under 37 CFR 1.20(d) is estimated to be \$110.00. Please charge the required fee to PE Applied Biosystems Deposit Account No. 01-2213. A copy of this sheet is enclosed for accounting purposes.			
7 Certification under 37 CFR 3 N 0000000 1114215 (SB) 114215 (SB) 1142 Hay be use	3.73(b) is required if d for making this ce	terminal disclaimer is signorification. See MPEP § 32	ed by the assignee (owner). 4.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.